Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 6.27B 5.72B 5.27B 4.79B 8.99B 581B 9.44B 64.09B 25.47B 317B 23.54B 23.05B 996B P/E 2026 *
-6.35x
P/E 2027 * -70.3x
Enterprise Value 6.33B 5.77B 5.31B 4.83B 9.07B 586B 9.53B 64.69B 25.71B 320B 23.76B 23.26B 1,005B EV / Sales 2026 *
8.82x
EV / Sales 2027 * 7.38x
Free-Float
98.33%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week+3.00%
Current month+13.09%
1 month+16.89%
3 months-5.98%
6 months+0.50%
Current year+21.70%
1 week 89.27
Extreme 89.27
98.39
1 month 80.24
Extreme 80.24
98.97
Current year 73.82
Extreme 73.82
130
1 year 63.23
Extreme 63.232
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 21/03/2019
Director of Finance/CFO 66 11/09/2023
President 48 16/01/2024
Director TitleAgeSince
Chairman 73 21/03/2019
Director/Board Member 55 07/11/2018
Director/Board Member 47 01/11/2018
Date Insider Type Main position Quantity % Market Cap. Importance
04/11/26 Exercice

Chief Executive Officer

60,000 0.0924%
16/10/26 Exercice

Controller/Auditor

32,224 0.0496%
09/10/26 Free

Chief Technology Officer

65,000 0.1001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%+3.00%+36.48%+197.43% 6.24B
-0.30%-5.62%+28.35%+127.66% 1,204B
+1.25%-4.60%+33.56%+80.57% 643B
+0.94%-2.80%+22.88%+106.94% 501B
-0.60%-2.39%+27.92%+67.00% 378B
+0.69%-9.00%+40.68%+31.42% 327B
+0.41%-4.81%+24.99%+51.91% 285B
+0.81%-3.72%-1.35%+30.72% 270B
-0.15%-6.73%+27.23%+64.15% 237B
-0.06%-0.91%+29.95%+120.58% 207B
Average +0.40%-3.73%+27.07%+87.84% 406B
Weighted average by Cap. +0.39%-4.70%+27.27%+88.48%

Financials

2026 *2027 *
Net sales 718M 654M 602M 548M 1.03B 66.45B 1.08B 7.33B 2.91B 36.3B 2.69B 2.64B 114B 869M 791M 729M 663M 1.24B 80.43B 1.31B 8.87B 3.53B 43.93B 3.26B 3.19B 138B
Net income -939M -855M -788M -717M -1.34B -86.93B -1.41B -9.59B -3.81B -47.48B -3.52B -3.45B -149B -100M -91.47M -84.28M -76.67M -144M -9.3B -151M -1.03B -408M -5.08B -377M -369M -15.94B
Net Debt 57.92M 52.75M 48.61M 44.22M 82.95M 5.36B 87.18M 592M 235M 2.93B 217M 213M 9.19B 135M 123M 113M 103M 193M 12.49B 203M 1.38B 547M 6.82B 506M 495M 21.4B
Projected Income Statement - Annual - Mirum Pharmaceuticals, Inc.
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
470
Date Price Change Volume
20/11/26 $96.12 +0.64% 1,044,263
19/11/26 $95.51 +3.27% 777,603
18/11/26 $92.49 +0.59% 498,221
17/11/26 $91.95 +0.40% 377,668
16/11/26 $91.58 -2.56% 506,487
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Mirum Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
96.12USD
Average target price
157.71USD
Spread / Average Target
+64.08%
  1. Stock Market
  2. Stocks
  3. MIRM Stock